Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Intangibles (2016 - 2025)

Cumberland Pharmaceuticals' Intangibles history spans 16 years, with the latest figure at $15.0 million for Q3 2025.

  • For Q3 2025, Intangibles fell 22.69% year-over-year to $15.0 million; the TTM value through Sep 2025 reached $15.0 million, down 22.69%, while the annual FY2024 figure was $18.0 million, N/A changed from the prior year.
  • Intangibles for Q3 2025 was $15.0 million at Cumberland Pharmaceuticals, down from $16.0 million in the prior quarter.
  • Across five years, Intangibles topped out at $34.5 million in Q1 2022 and bottomed at $15.0 million in Q3 2025.
  • The 5-year median for Intangibles is $25.4 million (2021), against an average of $24.5 million.
  • The largest annual shift saw Intangibles grew 27.7% in 2022 before it decreased 28.41% in 2024.
  • A 5-year view of Intangibles shows it stood at $24.0 million in 2021, then increased by 27.7% to $30.6 million in 2022, then dropped by 11.34% to $27.1 million in 2023, then crashed by 33.73% to $18.0 million in 2024, then dropped by 16.48% to $15.0 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Intangibles are $15.0 million (Q3 2025), $16.0 million (Q2 2025), and $17.0 million (Q1 2025).